Skip to main content

Navigation group

Type at least 3 characters
922 articles

Articles

Original Research

Published on 12 Jan 2022

Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom

in Translational Pharmacology

  • Pamella G. Gutierres
  • Diego R. Pereira
  • Nataly L. Vieira
  • Lilian F. Arantes
  • Nelson J. Silva
  • Kristian A. Torres-Bonilla
  • Stephen Hyslop
  • Karen Morais-Zani
  • Rosa M. B. Nogueira
  • Edward G. Rowan
Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom
Frontiers in Pharmacology
doi 10.3389/fphar.2021.812295
  • 3,531 views
  • 10 citations

Original Research

Published on 12 Jan 2022

AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

in Translational Pharmacology

  • Eslam E. Abd El-Fattah
  • Sameh Saber
  • Mahmoud E. Youssef
  • Hanan Eissa
  • Eman El-Ahwany
  • Noha A. Amin
  • Mohammed Alqarni
  • Gaber El-Saber Batiha
  • Ahmad J. Obaidullah
  • Mohamed M.Y. Kaddah
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma
Frontiers in Pharmacology
doi 10.3389/fphar.2021.720173
  • 7,579 views
  • 28 citations